Skip to main content

Published locations for Dual HER2 inhibition with pyrotinib-trastuzumab-docetaxel confers survival benefits in untreated HER2+ metastatic BC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Dual HER2 inhibition with pyrotinib-trastuzumab-docetaxel confers survival benefits in untreated HER2+ metastatic BC

User login

  • Reset your password
  • /content/dual-her2-inhibition-pyrotinib-trastuzumab-docetaxel-confers-survival-benefits-untreated
  • /hematology-oncology/article/266543/breast-cancer/dual-her2-inhibition-pyrotinib-trastuzumab